Truist Cuts Boston Scientific Price Target to $95 After $890M Electrophysiology Miss
Truist cut Boston Scientific’s price target to $95 from $120 and kept a Buy rating after Q4 revenue of $5.29 billion and $0.80 adjusted EPS matched estimates. Electrophysiology sales missed at $890 million versus $933 million expected, Watchman device sales slipped 1%, and 2026 organic revenue growth was lowered to 10%–11% from 15.8%.
1. Truist Cuts Price Target and Maintains Rating
Truist lowered Boston Scientific’s price target to $95 from $120 but maintained its Buy rating, citing an excessive share pullback that now trades at a discount to faster-growing peers.
2. Q4 Results Highlight Segment Misses
Boston Scientific reported Q4 revenue of $5.29 billion and $0.80 adjusted EPS in line with forecasts, while electrophysiology sales fell to $890 million versus $933 million expected and Watchman device sales were 1% below projections.
3. 2026 Growth Outlook Trimmed
The company guided 2026 organic revenue growth of 10%–11%, down from a 15.8% expansion in 2025, and set adjusted EPS between $3.43 and $3.49, with the midpoint slightly under consensus.